Genmab AS Financials
| GMAB Stock | USD 21.83 0.28 1.27% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.39 | 13.341 |
|
|
The financial analysis of Genmab AS is a critical element in measuring its lifeblood. Investors should not minimize Genmab AS's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Genmab | Select Account or Indicator |
Understanding current and past Genmab AS Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Genmab AS's financial statements are interrelated, with each one affecting the others. For example, an increase in Genmab AS's assets may result in an increase in income on the income statement.
Please note, the presentation of Genmab AS's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genmab AS's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Genmab AS's management manipulating its earnings.
Genmab AS Stock Summary
Genmab AS competes with Equillium, DiaMedica Therapeutics, Valneva SE, Vivani Medical, and Denali Therapeutics. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on NASDAQ Exchange in the United States.| Foreign Associate | Denmark |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US3723032062 |
| CUSIP | 372303206 |
| Location | Denmark |
| Business Address | Carl Jacobsens Vej |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.genmab.com |
| Phone | 45 70 20 27 28 |
| Currency | USD - US Dollar |
Genmab AS Key Financial Ratios
| Return On Equity | 0.15 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.38 % | ||||
| Price To Sales | 0.70 X | ||||
| Revenue | 16.47 B |
Genmab AS Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 15.1B | 21.1B | 24.6B | 30.3B | 35.3B | 37.1B | |
| Other Current Liab | 912M | 1.1B | 1.2B | 1.7B | 2.3B | 2.4B | |
| Net Debt | (3.4B) | (6.9B) | (8.5B) | (9.3B) | (14.1B) | (13.4B) | |
| Retained Earnings | 2.1B | 7.1B | 10.0B | 15.0B | 19.0B | 20.0B | |
| Accounts Payable | 839M | 145M | 350M | 1.7B | 2.3B | 2.4B | |
| Cash | 3.6B | 7.3B | 9.0B | 9.9B | 14.9B | 15.6B | |
| Other Current Assets | 10.4B | 249M | 31M | 143M | 164.5M | 156.2M | |
| Total Liab | 1.1B | 2.0B | 2.4B | 2.8B | 3.7B | 3.9B | |
| Total Current Assets | 14.0B | 18.8B | 22.7B | 28.4B | 33.1B | 34.8B | |
| Short Term Debt | 26M | 42M | 62M | 74M | 90M | 94.5M | |
| Intangible Assets | 470M | 338M | 254M | 146M | 101M | 192.7M | |
| Common Stock | 61.2M | 61.5M | 65M | 66M | 75.9M | 55.1M | |
| Net Receivables | 3.0B | 2.5B | 3.4B | 5.7B | 4.9B | 5.2B | |
| Inventory | (10.4B) | (249M) | (31M) | (143M) | 57M | 59.9M | |
| Net Tangible Assets | 13.6B | 18.8B | 21.9B | 27.3B | 31.4B | 33.0B | |
| Other Assets | 150M | 197M | 291M | 300M | 345M | 243.7M | |
| Net Invested Capital | 14.0B | 19.1B | 22.2B | 27.4B | 31.6B | 20.2B | |
| Net Working Capital | 13.0B | 17.5B | 21.2B | 26.6B | 30.7B | 19.1B |
Genmab AS Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 7M | 10M | 13M | 21M | 27M | 16.6M | |
| Operating Income | 2.6B | 6.3B | 3.0B | 6.4B | 5.3B | 5.6B | |
| Ebit | 2.6B | 6.3B | 2.9B | 6.8B | 5.3B | 5.6B | |
| Research Development | 2.4B | 3.1B | 4.2B | 5.6B | 7.6B | 8.0B | |
| Ebitda | 2.9B | 6.5B | 3.1B | 7.0B | 5.6B | 5.8B | |
| Income Before Tax | 2.9B | 5.9B | 4.0B | 7.0B | 5.6B | 5.9B | |
| Net Income | 2.2B | 4.8B | 3.0B | 5.5B | 4.4B | 4.6B | |
| Income Tax Expense | 693M | 1.1B | 975M | 1.5B | 1.3B | 1.3B | |
| Total Revenue | 5.4B | 10.1B | 8.5B | 14.6B | 16.5B | 17.3B | |
| Gross Profit | 5.4B | 10.1B | 8.5B | 14.6B | 16.2B | 17.1B | |
| Tax Provision | 693M | 1.1B | 975M | 1.5B | 1.3B | 690.5M | |
| Interest Income | 348M | 184M | 197M | 324M | 939M | 986.0M | |
| Net Interest Income | 334M | 174M | 184M | 303M | 912M | 957.6M |
Genmab AS Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 3.0B | 3.7B | 1.7B | 936M | 5.0B | 5.2B | |
| Free Cash Flow | 1.2B | 6.1B | 2.0B | 3.6B | 7.0B | 7.4B | |
| Depreciation | 139M | 259M | 248M | 362M | 295M | 309.8M | |
| Other Non Cash Items | (216M) | 409M | (997M) | (2.0B) | (622M) | (590.9M) | |
| Capital Expenditures | 111M | 307M | 252M | 317M | 376M | 394.8M | |
| Net Income | 2.9B | 5.9B | 4.0B | 7.0B | 5.6B | 5.9B | |
| End Period Cash Flow | 3.6B | 7.3B | 9.0B | 9.9B | 14.9B | 15.6B | |
| Investments | (2.0B) | (2.4B) | (709M) | (2.8B) | (976M) | (1.0B) | |
| Dividends Paid | 9M | 115M | 135M | 280M | 322M | 338.1M | |
| Change To Netincome | 211M | 422M | (314M) | (78M) | (70.2M) | (66.7M) |
Genmab Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genmab AS's current stock value. Our valuation model uses many indicators to compare Genmab AS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genmab AS competition to find correlations between indicators driving Genmab AS's intrinsic value. More Info.Genmab AS is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.73 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Genmab AS is roughly 1.36 . At present, Genmab AS's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genmab AS's earnings, one of the primary drivers of an investment's value.Genmab AS Systematic Risk
Genmab AS's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Genmab AS volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Genmab AS correlated with the market. If Beta is less than 0 Genmab AS generally moves in the opposite direction as compared to the market. If Genmab AS Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Genmab AS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Genmab AS is generally in the same direction as the market. If Beta > 1 Genmab AS moves generally in the same direction as, but more than the movement of the benchmark.
Genmab AS Thematic Clasifications
Genmab AS is part of Cash Cows investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Companies that have the ability to maintain consistent cash flow over time. Entities with stable and reliable earnings or profits, which allows them to pay consistent dividends to their shareholders
This theme covers Companies that have the ability to maintain consistent cash flow over time. Entities with stable and reliable earnings or profits, which allows them to pay consistent dividends to their shareholders. Get More Thematic Ideas
| Cash Cows | View |
Today, most investors in Genmab AS Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Genmab AS's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Genmab AS growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Genmab AS December 11, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Genmab AS help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Genmab AS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Genmab AS based on widely used predictive technical indicators. In general, we focus on analyzing Genmab Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Genmab AS's daily price indicators and compare them against related drivers.
| Information Ratio | (0.30) | |||
| Maximum Drawdown | 7.1 | |||
| Value At Risk | (3.15) | |||
| Potential Upside | 1.59 |
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |